Biocardia Inc's Comment on Sales, Marketing and Customers
The company targets leading cardiologists at high-volume hospitals and medical centers as initial adopters of its cell therapy systems, with plans to expand to a broader market segment. Its primary focus is on cardiologists and interventional cardiologists due to their history of early adoption and the significant unmet medical needs of heart failure patients. Operating within the biotechnology and pharmaceutical industries, the company faces competition from various firms developing cell-based and gene-based therapies for heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. Some potential competitors may also serve as collaborators or partners, particularly in cardiovascular indications requiring delivery platforms. The company holds a license and distribution agreement with Biomet Biologics, LLC for a point-of-care cell processing platform, which includes exclusive worldwide distribution rights and royalty obligations. Its preclinical and clinical partnerships involve payments, milestones, and revenue sharing from commercialization, regardless of whether the biotherapeutic product candidate is ultimately commercialized.
BioCardia, Inc., a leading developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced its intent to undergo a reverse stock split at a ratio of 1 post-split share for every 15 pre-split shares. The decision, approved by the company s stockholders and Board of Directors, is aimed at meeting the minimum bid price requirement for continued listing on The Nasdaq Capital Market. However, uncertainties regarding the stock price s post-split performance and continuity above pre-split levels remain. According to a recent report by BioCardia, Inc. Nasdaq: BCDA, the organization plans to effectuate a reverse stock split, which will become effective at 12:01 a...
BioCardia, a prominent biotechnology company specializing in cell therapy interventions for cardiovascular disorders, has recently unveiled the primary endpoint results of their CardiAMP Cell Therapy trial. The trial aimed to assess the efficacy and benefits of the company s cellular and cell-derived therapeutics in treating chronic myocardial ischemia, a serious cardiovascular condition. Additionally, BioCardia has been actively driving advancements in late-stage cell therapy interventions for cardiovascular disorders through their CardiAMP Heart Failure II Phase 3 Pivotal Study, which was recently approved by the FDA. Furthermore, the company has initiated CardiALLO Phase I/II Clinical Trial involving allo...
In a groundbreaking move for the field of regenerative medicine, BioCardia, a leader in cardiovascular therapies, has received approval from the Centers for Medicare and Medicaid Services (CMS) to provide reimbursement coverage for the confirmatory Phase III clinical trial of their innovative CardiAMP heart failure study. This milestone represents a significant step forward in the development of advanced therapeutic solutions for patients suffering from heart failure, and has the potential to revolutionize treatment options in the near future.A Milestone Achievement in Regenerative Medicine:By gaining the CMS s reimbursement coverage approval, BioCardia has overcome a critical hurdle in the pursuit of bringi...
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes BioCardia, Inc. (Nasdaq: BCDA), a renowned developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, recently made an important announcement regarding the potential approval of their CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) in Japan. In a crucial development, the Japan Pharmaceutical and Medical Device Agency (PMDA) minutes have provided support to BioCardia s understanding that their therapy may receive approval based on follow-up...
Biocardia Inc’s Comment on Sales, Marketing and Customers
The company targets leading cardiologists at high-volume hospitals and medical centers as initial adopters of its cell therapy systems, with plans to expand to a broader market segment. Its primary focus is on cardiologists and interventional cardiologists due to their history of early adoption and the significant unmet medical needs of heart failure patients. Operating within the biotechnology and pharmaceutical industries, the company faces competition from various firms developing cell-based and gene-based therapies for heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. Some potential competitors may also serve as collaborators or partners, particularly in cardiovascular indications requiring delivery platforms. The company holds a license and distribution agreement with Biomet Biologics, LLC for a point-of-care cell processing platform, which includes exclusive worldwide distribution rights and royalty obligations. Its preclinical and clinical partnerships involve payments, milestones, and revenue sharing from commercialization, regardless of whether the biotherapeutic product candidate is ultimately commercialized.
Sources:
Biocardia Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biocardia Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biocardia Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
